Edition:
United Kingdom

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

2.16USD
21 Sep 2018
Change (% chg)

$-0.05 (-2.26%)
Prev Close
$2.21
Open
$2.20
Day's High
$2.25
Day's Low
$2.16
Volume
11,996
Avg. Vol
74,742
52-wk High
$18.80
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Fibrocell Announces FDA Fast Track Designation Of FCX-013
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA FAST TRACK DESIGNATION OF FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA.FIBROCELL SCIENCE - PLANS TO MANUFACTURE FCX-013 AT CGMP CELL MANUFACTURING FACILITY LOCATED IN EXTON, PENNSYLVANIA.  Full Article

Fibrocell Reports Cash And Cash Equivalents Of About $15.4 Million
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.FIBROCELL SCIENCE INC - BOARD IS CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE IN APRIL.FIBROCELL SCIENCE INC - BOARD HAS ESTABLISHED A SPECIAL COMMITTEE TO EXPLORE AND EVALUATE POTENTIAL STRATEGIC ALTERNATIVES.FIBROCELL SCIENCE INC - AS OF JUNE 30, CO HAD CASH AND CASH EQUIVALENTS OF ABOUT $15.4 MILLION.FIBROCELL SCIENCE INC - CURRENT CASH POSITION WILL BE ABLE TO FUND OPERATIONS INTO Q4 2019.  Full Article

Fibrocell Announces $6.0 Mln Registered Direct Offering Priced At-The-Market
Tuesday, 29 May 2018 

May 29 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES $6.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.FIBROCELL SCIENCE - ENTERED DEFINITIVE AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR PURCHASE OF ABOUT 2 MILLION SHARES OF COMMON STOCK, AT $2.85/SHARE.FIBROCELL SCIENCE - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL AND PRE-CLINICAL DEVELOPMENT OF FCX-007 AND FCX-013.  Full Article

Fibrocell Announces One-For-Five Reverse Stock Split
Thursday, 24 May 2018 

May 24 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES ONE-FOR-FIVE REVERSE STOCK SPLIT.FIBROCELL SCIENCE - TO EFFECT 1-FOR-5 REVERSE STOCK SPLIT OF COMMON STOCK AT 5:00 PM ET TODAY.FIBROCELL SCIENCE - BEGINNING WITH OPENING OF TRADING ON MAY 25, COMMON STOCK WILL TRADE ON NASDAQ CAPITAL MARKET ON SPLIT-ADJUSTED BASIS.  Full Article

Fibrocell Reports Q1 Loss Per Share $0.11
Thursday, 10 May 2018 

May 10 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 LOSS PER SHARE $0.11.  Full Article

Fibrocell Reports 2017 Financial Results And Recent Highlights
Monday, 19 Mar 2018 

March 19 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.  Full Article

Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB).FIBROCELL SCIENCE INC - FCX-007, CO'S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION.  Full Article

Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Fibrocell Science Inc ::FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING.  Full Article

Fibrocell Science Q3 loss per share $‍0.02​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Fibrocell Science Inc :Fibrocell reports third quarter 2017 financial results and recent highlights.Company believes that its cash and cash equivalents at September 30, 2017 will be sufficient to fund operations into Q2 of 2018​.Fibrocell expects to submit IND application for FCX-013 to FDA in Q4 of 2017, and initiate a human safety clinical trial in 2018​.Fibrocell Science Inc qtrly loss per share $‍0.02​.  Full Article

Fibrocell Science files for common stock offering of up to $23 mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Fibrocell Science Inc ::Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​.  Full Article

BRIEF-Fibrocell Reports Q1 Loss Per Share $0.11

* FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS